Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 6/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874107 | 1.00 | CHRM4 (0.39) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL3882565 | 0.93 | BRAF (0.39) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL3877065 | 0.93 | BRAF (0.39) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL13897672 | 0.86 | TRPV1 (0.50) | — | |
| SCHEMBL3875629 | 0.86 | TRPV1 (0.50) | — | |
| SCHEMBL3874646 | 0.86 | TRPV1 (0.50) | — | |
| SCHEMBL3875205 | 0.85 | OGA (0.38) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL3881497 | 0.85 | OGA (0.38) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL3884682 | 0.84 | ACHE (0.38) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL13898195 | 0.84 | ACHE (0.38) | CHRM4CHRM2CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1720868-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077944-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | CHRM4 697/4885CHRM2 689/4885CHRM5 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.